Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

NCT07146100 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-08-28
Last updated
2026-08-18

Condition(s) studied

Chronic Hepatitis B

Study summary

This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Capable of giving informed consent. * Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study. Exclusion Criteria: * Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137. * Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.

Primary outcome measure(s)

  • Percentage of participants maintained complete response(defined as HBsAg < 0.05IU/mL and HBV DNA < lower limit of quantification). — Up to 80 weeks

Trial sites (37)

FacilityCityRegionStatus
AusperBio Investigational Site Hefei Anhui Not Yet Recruiting
AusperBio Investigational Site Beijing Beijing Municipality Not Yet Recruiting
AusperBio Investigational Site Chongqing Chongqing Municipality Recruiting
AusperBio Investigational Site Chongqing Chongqing Municipality Not Yet Recruiting
AusperBio Investigational Site Fuzhou Fujian Recruiting
AusperBio Investigational Site Xiamen Fujian Not Yet Recruiting
AusperBio Investigational Site Lanzhou Gansu Not Yet Recruiting
AusperBio Investigational Site Foshan Guangdong Not Yet Recruiting
AusperBio Investigational Site Guangzhou Guangdong Recruiting
AusperBio Investigational Site Guangzhou Guangdong Recruiting
AusperBio Investigational Site Guangzhou Guangdong Not Yet Recruiting
AusperBio Investigational Site Guangzhou Guangdong Not Yet Recruiting
AusperBio Investigational Site Shenzhen Guangdong Not Yet Recruiting
AusperBio Investigational Site Shenzhen Guangdong Not Yet Recruiting
AusperBio Investigational Site Liuzhou Guangxi Not Yet Recruiting
AusperBio Investigational Site Nanning Guangxi Not Yet Recruiting
AusperBio Investigational Site Zunyi Guizhou Not Yet Recruiting
AusperBio Investigational Site Haikou Hainan Not Yet Recruiting
AusperBio Investigational Site Zhengzhou Henan Not Yet Recruiting
AusperBio Investigational Site Wuhan Hubei Not Yet Recruiting
AusperBio Investigational Site Changsha Hunan Not Yet Recruiting
AusperBio Investigational Site Changsha Hunan Not Yet Recruiting
AusperBio Investigational Site Changhou Jiangsu Recruiting
AusperBio Investigational Site Nanjing Jiangsu Not Yet Recruiting
AusperBio Investigational Site Zhenjiang Jiangsu Recruiting
AusperBio Investigational Site Nanchang Jiangxi Not Yet Recruiting
AusperBio Investigational Site Changchun Jilin Recruiting
AusperBio Investigational Site Shenyang Liaoning Not Yet Recruiting
AusperBio Investigational Site Shanghai Shanghai Municipality Not Yet Recruiting
AusperBio Investigational Site Taiyuan Shanxi Not Yet Recruiting
AusperBio Investigational Site Xi’an Shanxi Not Yet Recruiting
AusperBio Investigational Site Chengdu Sichuan Not Yet Recruiting
AusperBio Investigational Site Chengdu Sichuan Not Yet Recruiting
AusperBio Investigational Site Kunming Yunnan Not Yet Recruiting
AusperBio Investigational Site Hangzhou Zhejiang Recruiting
AusperBio Investigational Site Hangzhou Zhejiang Not Yet Recruiting
AusperBio Investigational Site Hangzhou Zhejiang Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07146100 on ClinicalTrials.gov ↗ ← All trials in China